A Phase IB Study of TTI-621 and TTI-622 in Combination with Daratumumab Hyaluronidase-fihj in People with Multiple Myeloma

Share
Print

Full Title

A Phase Ib Study Of The Combination Of CD47 Blockade With SIRP-Alpha FC Fusion Proteins (TTI-621 Or TTI-622) And Daratumumab Hyaluronidase-fihj For Patients With Relapsed or Refractory Multiple Myeloma

Purpose

The purpose of this study is to find the highest doses of the investigational drugs TTI-621 and TTI-622 that can be given in combination with daratumumab hyaluronidase-fihj in people with multiple myeloma that has come back or continued to grow despite treatment. TTI-621 and TTI-622 each work by helping the immune system find and kill cancer cells.

Patients in this study will receive either TTI-621 or TTI-622 (but not both) in combination with daratumumab hyaluronidase-fihj. TTI-621 and TTI-622 are given intravenously (by vein). Daratumumab hyaluronidase-fihj is given as an injection subcutaneously (under the skin).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have multiple myeloma that persists despite at least three prior regimens of therapy.
  • Patients should recover from the serious side effects of previous treatments before receiving the study treatment.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

For more information about this study and to ask about eligibility, please contact the office of Dr. Alexander Lesokhin at 212-639-3069.

Protocol

21-122

Phase

I

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators